Related Experiment Video
Updated: Dec 28, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[EGFR molecular characterization in non-small cell bronchic cancer: comparative prospective study by NGS and Idylla
Louise-Marie Chevalier1, Amandine Billaud1, Christophe Passot2
1Département de Biopathologie, Institut de Cancérologie de l'Ouest, site Paul Papin, 15, rue André Boquel, 49 055 Angers cedex 02, France; CRCINA U1232, Inserm, Université de Nantes, Université d'Angers, 4, rue Larrey, Angers, France.
Introduction:
Detection of genetic alterations in the EGFR tyrosine kinase domain is a major concern in the management of non-small cell lung cancer because it conditions access to tyrosine kinase inhibitors. In practice, it is possible to characterize only well-documented mutations or to sequence all relevant EGFR exons and also other targets of theranostic interest. This prospective study compares the targeted EGFR characterization on Idylla platform (Biocartis) and a more extensive one by next generation sequencing using Ion Torrent technology.
Material And Methods:
A total of 100 formalin-fixed paraffin-embedded tumour samples were tested simultaneously by both techniques under the conditions recommended by the suppliers. The comparison covered all technical and practical aspects of the laboratory.
Results:
At least one EGFR mutation of interest for tyrosine kinase inhibitors for 9 and 7 samples was detected respectively by sequencing and by the Idylla system. For three samples, EGFR sensitive mutations to tyrosine kinase inhibitors were detected only by next-generation sequencing. In addition, for 37 samples, mutations of clinical interest outside EGFR were characterized by sequencing and communicated to the prescriber.
Conclusion:
Idylla technology allows the rapid characterization of a majority of EGFR variants. The result can be optimized by careful analysis of the amplification curves with the Idylla Explore tool or by increasing the amount of initial material. A complementary new generation sequencing analysis for non-contributory results by Idylla should also be recommended.
Insights
The Idylla system rapidly identifies most EGFR mutations in non-small cell lung cancer, but next-generation sequencing detects additional clinically relevant mutations. Further analysis or sequencing may be needed for comprehensive results.
Area of Science:
- Oncology
- Genetics
- Molecular Diagnostics
Background:
- Epidermal growth factor receptor (EGFR) mutations are critical for non-small cell lung cancer (NSCLC) treatment decisions.
- Current methods include targeted mutation detection or comprehensive sequencing of EGFR exons and other theranostic targets.
- This study evaluates targeted EGFR testing using the Idylla platform against comprehensive next-generation sequencing (NGS).
Purpose of the Study:
- To compare the performance of the Idylla platform for targeted EGFR mutation detection with NGS.
- To assess the technical and practical aspects of both diagnostic approaches in a clinical laboratory setting.
- To determine the concordance and identify discrepancies in EGFR mutation detection between the two methods.
Main Methods:
- 100 formalin-fixed paraffin-embedded NSCLC tumor samples were analyzed concurrently using both Idylla and Ion Torrent NGS.
- Both techniques were performed according to manufacturer guidelines.
- A comprehensive comparison of technical and practical laboratory aspects was conducted.
Main Results:
- EGFR mutations actionable by tyrosine kinase inhibitors (TKIs) were detected in 9 samples by sequencing and 7 by Idylla.
- Three samples showed TKI-sensitive EGFR mutations exclusively identified by NGS.
- Sequencing also identified mutations outside of EGFR in 37 samples, providing additional clinical information.
Conclusions:
- The Idylla platform offers rapid detection of most EGFR variants.
- Optimizing Idylla results may involve analyzing amplification curves or increasing sample input.
- Complementary NGS is recommended for non-conclusive Idylla results and comprehensive mutation profiling.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016